MinervaX initiates Phase I GBS vaccine trial in older people

MinervaX has initiated a Phase I clinical trial of its new GBS vaccine to assess the safety and immunogenicity in the older adult population with Group B Streptococcus (GBS).

The trial at Centre for Vaccinology (CEVAC) in Ghent, Belgium, will evaluate two doses of the GBS vaccine in older adults aged 55 to 75 years with and without underlying medical conditions.